ESCC Molecular Subtypes Based on Multidimensional Features of p53 and Their Clinical Significance

Specific research design

1. Collect information on all clinical cases of esophageal cancer in the study, including gender, age, time of diagnosis, time of death, treatment information, TNM staging, tumor size, location, etc.
2. Perform DNA sequencing on the collected esophageal cancer tissue samples, identify gene mutation sites, and group them according to different types of mutations.
3. Perform ELISA on the collected serum of esophageal cancer patients to distinguish between groups with negative and positive autoantibodies.
4. Perform immunohistochemistry on tumor tissue slices collected from esophageal cancer patients, observe the expression of mutant P53 protein, and obtain samples with positive immunohistochemistry for P53 protein.
5. Based on the presence or absence of P53 mutations, the expression of mutant P53 protein in immunohistochemistry, and the positive or negative autoantibodies in serum, further subtype classification criteria will be developed.
6. Associate different subtypes of esophageal cancer with clinical and pathological features, identify their respective characteristics, and provide guidance for clinical diagnosis, treatment, and prognosis. Univariate and multivariate survival analysis of clinical pathological parameters and the correlation between this subtype and DFS and OS in cancer patients; Kaplan Meier curve analysis of the relationship between this subtype and patient survival, as well as its expression for cancer risk assessment.

Specific research design

1. Collect information on all clinical cases of esophageal cancer in the study, including gender, age, time of diagnosis, time of death, treatment information, TNM staging, tumor size, location, etc.
2. Perform DNA sequencing on the collected esophageal cancer tissue samples, identify gene mutation sites, and group them according to different types of mutations.
3. Perform ELISA on the collected serum of esophageal cancer patients to distinguish between groups with negative and positive autoantibodies.
4. Perform immunohistochemistry on tumor tissue slices collected from esophageal cancer patients, observe the expression of mutant P53 protein, and obtain samples with positive immunohistochemistry for P53 protein.
5. Based on the presence or absence of P53 mutations, the expression of mutant P53 protein in immunohistochemistry, and the positive or negative autoantibodies in serum, further subtype classification criteria will be developed.
6. Associate different subtypes of esophageal cancer with clinical and pathological features, identify their respective characteristics, and provide guidance for clinical diagnosis, treatment, and prognosis.

Univariate and multivariate survival analysis of clinical pathological parameters and the correlation between this subtype and DFS and OS in cancer patients;